Immunoregulation in Inflammatory Bowel Diseases - Current Understanding and Innovation

Advances in the pathogenesis of inflammatory bowel disease.- Innate immune responses in inflammatory bowel disease.- The adaptive immune responses in inflammatory bowel disease.- Relevance of bacteria in the pathogenesis of inflammatory bowel disease.- Taking a toll on MD-2 in inflammatory bowel disease.- Optimization in therapy through improved disease classification?.- Classification of inflammatory bowel disease can only be based on the clinical phenotype.- Use of serology and genetics to differentiate inflammatory bowel disease phenotypes.- Do biomarkers help to optimize therapy in inflammatory bowel disease?.- Role of pharmacogenetics in the management of inflammatory bowel diseases.- Conventional immunomodulator therapy.- State-of-the-art therapy in accordance with guidelines.- Increased risk of morbidity associated with immunomodulatory treatment in patients with inflammatory bowel diseases.- Can immunomodulatory therapy be improved by metabolite measurement and combination therapy?.- Relevance of biologics.- Top-down therapy for inflammatory bowel disease.- ’step-up’ versus ‘top-down’ strategies in inflammatory bowel disease — what do we know in 2006?.- Importance of mucosal healing in Crohn’s disease and ulcerative colitis.- State-of-the-Art Lecture: Distinct antibacterial-defensin deficiencies in small intestinal and colonic Crohn’s disease.- New therapeutic approaches (Part I).- Oligonucleotides — new therapeutic approaches.- Probiotics in inflammatory bowel disease.- Helminth ova therapy for inflammatory bowel disease.- Retarded release phosphatidylcholine: a new therapeutic option for ulcerative colitis.- Topical steroids — rectal application.- New therapeutic approaches (Part II).- Apheresis.- The evolving understanding and therapy ofCrohn’s disease: innate immunity and sargramostim (GM-CSF).- Immunosuppression with tacrolimus, everolimus and sirolimus.- T-cell modulating antibodies in inflammatory bowel disease.